FR15C0068I2 - Derives de diamine - Google Patents

Derives de diamine

Info

Publication number
FR15C0068I2
FR15C0068I2 FR15C0068C FR15C0068C FR15C0068I2 FR 15C0068 I2 FR15C0068 I2 FR 15C0068I2 FR 15C0068 C FR15C0068 C FR 15C0068C FR 15C0068 C FR15C0068 C FR 15C0068C FR 15C0068 I2 FR15C0068 I2 FR 15C0068I2
Authority
FR
France
Prior art keywords
diamine derivatives
diamine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0068C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27482359&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0068(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/JP2002/006141 external-priority patent/WO2003000680A1/fr
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of FR15C0068I1 publication Critical patent/FR15C0068I1/fr
Application granted granted Critical
Publication of FR15C0068I2 publication Critical patent/FR15C0068I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FR15C0068C 2001-06-20 2015-10-09 Derives de diamine Active FR15C0068I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001187105 2001-06-20
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (fr) 2001-06-20 2002-03-20 Derives de diamine
PCT/JP2002/006141 WO2003000680A1 (fr) 2001-06-20 2002-06-20 Derives de diamine

Publications (2)

Publication Number Publication Date
FR15C0068I1 FR15C0068I1 (fr) 2015-12-04
FR15C0068I2 true FR15C0068I2 (fr) 2016-04-22

Family

ID=27482359

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0068C Active FR15C0068I2 (fr) 2001-06-20 2015-10-09 Derives de diamine

Country Status (13)

Country Link
US (7) US7365205B2 (fr)
EP (1) EP2343290A1 (fr)
AR (1) AR036102A1 (fr)
BE (1) BE2015C046I2 (fr)
CY (2) CY1113054T1 (fr)
FR (1) FR15C0068I2 (fr)
HK (1) HK1092461A1 (fr)
MY (1) MY153231A (fr)
NL (1) NL300760I2 (fr)
PT (1) PT1405852E (fr)
TW (1) TWI298066B (fr)
WO (1) WO2003000657A1 (fr)
ZA (1) ZA200309866B (fr)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
EP1405852B9 (fr) * 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Derives de diamine
CN100545160C (zh) * 2001-08-09 2009-09-30 第一制药株式会社 二胺衍生物
US20090286791A1 (en) * 2001-11-27 2009-11-19 Takeda Pharmaceutical Company Limited Amide Compounds
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
WO2005032490A2 (fr) * 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Diamines cycliques et derives comme inhibiteurs du facteur xa
KR101170179B1 (ko) * 2003-11-12 2012-07-31 다이이찌 산쿄 가부시키가이샤 티아졸 유도체의 제조법
CZ2006427A3 (cs) * 2003-12-29 2006-11-15 Sepracor Inc. Pyrrolové a pyrazolové inhibitory DAAO
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
JP2008504279A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
US7687665B2 (en) * 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
JP2008504274A (ja) * 2004-06-24 2008-02-14 インサイト・コーポレイション アミド化合物およびその医薬としての使用
CA2570694A1 (fr) * 2004-06-24 2006-02-02 Incyte Corporation Composes amido et utilisations de ces derniers en tant que produits pharmaceutiques
AU2005258248A1 (en) * 2004-06-24 2006-01-05 Incyte Corporation Amido compounds and their use as pharmaceuticals
MX2007001540A (es) * 2004-08-10 2007-04-23 Incyte Corp Compuestos amido y sus usos como farmaceuticos.
US7499687B2 (en) * 2004-11-09 2009-03-03 Theta Microelectronics, Inc. Wireless transmitter DC offset recalibration
US8110581B2 (en) * 2004-11-10 2012-02-07 Incyte Corporation Lactam compounds and their use as pharmaceuticals
MX2007005820A (es) * 2004-11-18 2007-07-18 Incyte Corp Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos.
AU2006215788B2 (en) * 2005-02-18 2011-10-20 Acino Pharma Ag Novel processes for the preparation of a 2H-chromene
KR20070116032A (ko) * 2005-03-31 2007-12-06 다이이찌 산쿄 가부시키가이샤 트리아민 유도체
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
US7825155B2 (en) 2005-09-14 2010-11-02 Dainippon Sumitomo Pharma Co., Ltd. Oxindole derivative as feeding control agent
CA2621640C (fr) * 2005-09-16 2013-10-29 Daiichi Sankyo Company, Limited Derive de diamine optiquement actif et procede de synthese dudit derive
WO2007038138A2 (fr) * 2005-09-21 2007-04-05 Incyte Corporation Utilisation pharmaceutique de composes amido
US8193207B2 (en) * 2005-12-05 2012-06-05 Incyte Corporation Lactam compounds and methods of using the same
ES2566479T3 (es) * 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
US7998959B2 (en) * 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
KR20080091503A (ko) * 2006-01-31 2008-10-13 인사이트 코포레이션 아미도 화합물 및 약제로서의 이의 용도
US20070213311A1 (en) * 2006-03-02 2007-09-13 Yun-Long Li Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007103719A2 (fr) * 2006-03-03 2007-09-13 Incyte Corporation MODULATEURS DE LA 11-β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
EP2816024B8 (fr) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Amines chiraux
CA2649677A1 (fr) * 2006-05-01 2007-11-15 Incyte Corporation Urees tetrasubstituees modulateurs de la 11-.beta. hydroxyl steroid deshydrogenase de type 1
WO2007137066A2 (fr) * 2006-05-17 2007-11-29 Incyte Corporation Inhibiteurs hétérocycliques de la déshydrogénase du stéroïde hydroxyle 11-b de type 1 et leurs procédés d'utilisation
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008026563A1 (fr) 2006-08-30 2008-03-06 Shionogi & Co., Ltd. Dérivé d'hydrazine amide
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
JP5420534B2 (ja) 2007-05-31 2014-02-19 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害薬としてのフェニル置換シクロアルキルアミン
DE102007028406A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028407A1 (de) 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
GB0721333D0 (en) * 2007-10-31 2007-12-12 Motac Neuroscience Ltd Medicaments
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
US9776963B2 (en) 2008-11-10 2017-10-03 The Trustees Of The University Of Pennsylvania Small molecule CD4 mimetics and uses thereof
WO2010067824A1 (fr) 2008-12-12 2010-06-17 第一三共株式会社 Procédé de synthèse d'un acide carboxylique optiquement actif
CA2747427C (fr) 2008-12-17 2015-10-13 Daiichi Sankyo Company, Limited Methode de production d'un derive de diamine
WO2010082531A1 (fr) 2009-01-13 2010-07-22 第一三共株式会社 Inhibiteur d'un facteur actif de la coagulation sanguine
EP2407457B1 (fr) * 2009-03-10 2015-04-22 Daiichi Sankyo Company, Limited Procédé de production d'un dérivé de diamine
WO2010104106A1 (fr) 2009-03-13 2010-09-16 第一三共株式会社 Procédé de production d'un dérivé diamine optiquement actif
WO2010131663A1 (fr) * 2009-05-15 2010-11-18 第一三共株式会社 Derive d'oxamide
TW201102064A (en) 2009-06-18 2011-01-16 Daiichi Sankyo Co Ltd Pharmaceutical composition having improved dissolution property
FR2948372B1 (fr) 2009-07-21 2011-07-22 Servier Lab Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2011017634A2 (fr) * 2009-08-07 2011-02-10 Sepracore Inc. Promédicaments d'inhibiteurs hétérocycliques fusionnés de la d-aminoacide oxydase
EP2540318B1 (fr) 2010-02-22 2018-10-24 Daiichi Sankyo Company, Limited Préparation solide à libération prolongée pour utilisation orale
EP2540317A4 (fr) 2010-02-22 2014-04-16 Daiichi Sankyo Co Ltd Préparation solide à libération prolongée pour usage oral
EP2540294B1 (fr) 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Préparation solide à libération prolongée pour usage oral
JP5692873B2 (ja) * 2010-03-19 2015-04-01 第一三共株式会社 ジアミン誘導体の結晶およびその製造方法
ES2601884T3 (es) 2010-03-19 2017-02-16 Daiichi Sankyo Company, Limited Procedimiento para mejorar la capacidad de disolución de un anticoagulante
WO2011149110A1 (fr) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Nouvelle composition pour la prévention et/ou le traitement de la thromboembolie
CN103080078B (zh) 2010-07-02 2015-02-11 第一三共株式会社 光学活性二胺衍生物盐的制备方法
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CA2824885A1 (fr) 2011-01-19 2012-07-26 Bayer Intellectual Property Gmbh Proteines de liaison a des inhibiteurs de facteurs de coagulation
WO2013008733A1 (fr) 2011-07-08 2013-01-17 第一三共株式会社 Procédé de contrôle de la qualité de produit
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
US20130158069A1 (en) 2011-12-14 2013-06-20 Daiichi Sankyo Company, Limited Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment
CN102659757B (zh) * 2012-04-24 2013-11-06 南京药石药物研发有限公司 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法
TWI566786B (zh) 2012-09-03 2017-01-21 第一三共股份有限公司 含有氫化嗎啡酮鹽酸鹽之經口用徐放性醫藥組成物
US9447039B2 (en) 2012-09-07 2016-09-20 Novartis Ag Indole carboxamide derivatives and uses thereof
EP2922833A1 (fr) 2012-11-23 2015-09-30 Daiichi Sankyo Co., Ltd. Procédé de préparation de (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
CA2907243C (fr) 2013-03-15 2021-12-28 Celgene Avilomics Research, Inc. Composes de dihydropyrimidopyrimidinones substitues et leurs compositions pharmaceutiques utilisees en tant qu'inhibiteur du gene fgfr4
EP2980090A4 (fr) * 2013-03-29 2016-11-09 Daiichi Sankyo Co Ltd Procédé de production de (1s,4s,5s)-4-bromo-6- oxabicyclo[3.2.1]octane-7-one
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2015028919A1 (fr) 2013-08-29 2015-03-05 Daiichi Sankyo Company, Limited Agent pour le traitement et la prévention du cancer
EP3125939A1 (fr) 2014-03-31 2017-02-08 Daiichi Sankyo Co., Ltd. Utilisation d'un inhibiteur du facteur xa dans le traitement et la prévention des hémorragies et troubles associés chez les patients sensibles aux antagonistes de la vitamine k utilisés comme anticoagulants
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
WO2016025681A1 (fr) 2014-08-13 2016-02-18 The Trustees Of The University Of Pennsylvania Inhibiteurs de pénétration du vih-1 et leurs méthodes d'utilisation
CN104529729B (zh) * 2014-12-31 2016-03-30 浙江永太科技股份有限公司 一种2-氟-3-氯苯甲醛的制备方法
TWI571460B (zh) 2016-03-14 2017-02-21 中化合成生技股份有限公司 二胺衍生物之製造方法
EP3484893A1 (fr) 2016-07-13 2019-05-22 Mylan Laboratories Ltd. Sel de (1s,2r,4s)-1,2-amino-n, n-diméthylcyclohexane-4-carboxamide protégé par des amines
WO2018069769A1 (fr) 2016-10-13 2018-04-19 Daiichi Sankyo Company, Limited Composition pharmaceutique permettant d'inhiber la formation de néointima d'un vaisseau sanguin
US10301322B2 (en) 2016-12-27 2019-05-28 Apotex Inc. Processes for the preparation of edoxaban and intermediates thereof
CA3061238A1 (fr) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Derives d'indole utilises en tant qu'inhibiteurs de pompe d'efflux
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
TWI826474B (zh) 2018-06-27 2023-12-21 日商第一三共股份有限公司 包含二胺衍生物之顆粒劑、以及其用途及製造方法
US20210353764A1 (en) 2018-09-26 2021-11-18 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
AU2019351427A1 (en) 2018-09-30 2021-04-15 Changzhou Hansoh Pharmaceutical Co., Ltd. Anti-B7H3 antibody-exatecan analog conjugate and medicinal use thereof
CN109942600B (zh) * 2019-04-15 2021-08-20 内蒙古京东药业有限公司 一种依度沙班的制备方法
JP2022540114A (ja) 2019-07-10 2022-09-14 バイエル・アクチエンゲゼルシヤフト ２－（フェニルイミノ）－１，３－チアゾリジン－４－オン類の調製方法
KR102333564B1 (ko) 2019-11-28 2021-12-01 동방에프티엘(주) 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로
AU2020402006A1 (en) 2019-12-12 2022-07-07 Jiangsu Hengrui Medicine Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
AU2021210074A1 (en) 2020-01-22 2022-07-28 Jiangsu Hengrui Medicine Co., Ltd. Anti-TROP-2 antibody-exatecan analog conjugate and medical use thereof
BR112022019042A2 (pt) 2020-03-25 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Método de preparação para conjugado anticorpo-fármaco
MX2022011770A (es) 2020-03-25 2022-10-18 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene un conjugado de anticuerpo-farmaco y uso de la misma.
WO2021190583A1 (fr) 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Conjugué d'anticorps anti-psma-exatécan et son utilisation médicale
EP4162954A1 (fr) 2020-06-08 2023-04-12 Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. Médicament à base de camptothécine ayant une unité de liaison hydrophile à stabilité élevée et conjugué de celui-ci
EP4262760A1 (fr) 2020-12-18 2023-10-25 KRKA, d.d., Novo mesto Formulation d'edoxaban ne contenant pas d'alcools de sucre
KR20220087933A (ko) 2020-12-18 2022-06-27 엠에프씨 주식회사 디아민 유도체의 제조방법
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN116120460A (zh) 2021-11-15 2023-05-16 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
CN114456194B (zh) * 2021-12-14 2023-07-07 浙江九洲药业股份有限公司 甲苯磺酸艾多沙班的中间体及其制备方法
CN115583900A (zh) * 2022-04-29 2023-01-10 张邦成都生物医药科技有限公司 一种高纯度依度沙班中间体的制备方法
WO2023223346A1 (fr) 2022-05-16 2023-11-23 Mylan Laboratories Limited Procédé amélioré pour la préparation d'un intermédiaire d'édoxaban

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3324086A (en) * 1964-02-26 1967-06-06 Monsanto Co Polyamides containing fused heterocycle units
JPS63500796A (ja) * 1985-06-07 1988-03-24 ジ・アップジョン・カンパニ− アミノシクロアルキルアミドの抗不整脈剤用途
WO1992004017A1 (fr) * 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamides et leurs enantiomeres en tant qu'agents anticonvulsivants
IL100576A (en) 1991-01-18 1995-11-27 Eli Lilley And Company Cephalosporin antibiotics
WO1993010022A1 (fr) 1991-11-14 1993-05-27 Frutin Bernard D Recipient sous pression
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
CA2157412A1 (fr) 1993-03-03 1994-09-15 Julia Marie Heerding Balanoides
WO1994021599A1 (fr) 1993-03-17 1994-09-29 Meiji Seika Kabushiki Kaisha Nouveau compose a activite inhibitrice de l'agregation des plaquettes
KR970001164B1 (ko) 1993-06-09 1997-01-29 한국과학기술연구원 세팔로스포린계 항생제 및 그의 제조방법
CA2174516A1 (fr) 1993-10-19 1995-04-27 Yoshiharu Ikeda Derive d'acide 2,3-diaminopropionique
TW270114B (fr) 1993-10-22 1996-02-11 Hoffmann La Roche
US5525042A (en) 1993-11-08 1996-06-11 Clearline Systems, Inc. Liquid pump with compressed gas motive fluid
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
WO1995032965A1 (fr) 1994-06-01 1995-12-07 Yamanouchi Pharmaceutical Co. Ltd. Derive de l'oxadiazole et composition medicinale a base de ce dernier
IL115420A0 (en) 1994-09-26 1995-12-31 Zeneca Ltd Aminoheterocyclic derivatives
US5719144A (en) 1995-02-22 1998-02-17 Merck & Co., Inc. Fibrinogen receptor antagonists
JP3038016B2 (ja) 1995-04-07 2000-05-08 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼを阻害する、カルボニルピペラジニルおよびカルボニルピペリジニル化合物
ZA963391B (en) 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
US5726126A (en) 1995-06-02 1998-03-10 American Cyanamid Company 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US5852045A (en) 1995-10-19 1998-12-22 Merck & Co., Inc. Fibrinogen receptor antagonists
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
GB9602294D0 (en) 1996-02-05 1996-04-03 Zeneca Ltd Heterocyclic compounds
ATE269312T1 (de) 1996-04-17 2004-07-15 Bristol Myers Squibb Pharma Co N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
US5668159A (en) 1996-05-08 1997-09-16 The Dupont Merck Pharmaceutical Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists
BR9711135A (pt) 1996-08-14 1999-08-17 Zeneca Ltd Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
UA56197C2 (uk) 1996-11-08 2003-05-15 Зенека Лімітед Гетероциклічні похідні
US6440972B1 (en) 1997-02-13 2002-08-27 Zeneca Limited Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
IT1291823B1 (it) 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
EP0986551B1 (fr) 1997-05-30 2006-08-02 Takeda Pharmaceutical Company Limited Derives de la sulfonamide, leur production et leurs utilisations
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
CA2294126A1 (fr) 1997-06-26 1999-01-07 Douglas Wade Beight Agents antithrombotiques
AU8270898A (en) 1997-06-26 1999-01-19 Eli Lilly And Company Antithrombotic agents
ATE306261T1 (de) 1997-06-26 2005-10-15 Lilly Co Eli Antithrombosemittel
GB9715895D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
GB9715894D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
BR9815377A (pt) 1997-09-30 2001-01-16 Daiichi Pharmaceutical Co Ltda Derivados de sulfonil
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
US6130349A (en) * 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
EP0937723A1 (fr) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Nouveaux sulfonamides, procédé pour leur préparation et médicaments les contenant
EP0937711A1 (fr) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Thiobenzamides, procédé pour leur préparation et médicaments les contenant
GB9807104D0 (en) 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
AU767409B2 (en) 1998-04-21 2003-11-06 Du Pont Pharmaceuticals Company 5-aminoindeno(1,2-C)pyrazol-4-ones as anti-cancer and anti-proliferative agents
EP1082321B1 (fr) 1998-05-02 2004-11-17 AstraZeneca AB Derives heterocycliques inhibant le facteur xa
GB9809350D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Novel salt
GB9809349D0 (en) 1998-05-02 1998-07-01 Zeneca Ltd Heterocyclic derivatives
AU4631499A (en) 1998-06-30 2000-01-17 Chirotech Technology Limited The preparation of arylphosphines
JP2000086659A (ja) 1998-07-14 2000-03-28 Takeda Chem Ind Ltd オクタヒドロピリド［１，２―ａ］ピラジン誘導体
TW434207B (en) 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6303625B1 (en) 1998-07-27 2001-10-16 Ortho-Mcneil Pharmaceutical, Inc. Triazolopyridines for the treatment of thrombosis disorders
WO2000009480A1 (fr) 1998-08-11 2000-02-24 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives sulfonyle
EP1140905B1 (fr) 1998-12-23 2003-05-14 Eli Lilly And Company AMIDES HETEROAROMATIQUES COMME INHIBITEURS DU FACTEUR Xa
JP2002533454A (ja) 1998-12-23 2002-10-08 イーライ・リリー・アンド・カンパニー 芳香族アミド類
EP1140881B1 (fr) 1998-12-23 2006-05-17 Eli Lilly And Company Amides antithrombotiques
AU2364000A (en) 1998-12-24 2000-07-31 Eli Lilly And Company Heterocyclic amides as inhibitors of factor xa
GB9902989D0 (en) 1999-02-11 1999-03-31 Zeneca Ltd Heterocyclic derivatives
AU2241400A (en) 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
JP4390024B2 (ja) 1999-04-23 2009-12-24 アステラス製薬株式会社 新規なジアゼパン誘導体又はその塩
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
AU5283600A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
EP1192132B1 (fr) 1999-06-14 2005-09-07 Eli Lilly And Company Composes
EP1185488A1 (fr) 1999-06-15 2002-03-13 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
GB9914342D0 (en) 1999-06-19 1999-08-18 Zeneca Ltd Compound
JP2001011071A (ja) 1999-06-25 2001-01-16 Mochida Pharmaceut Co Ltd アミノアルキルスルホンアミド誘導体
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
GB9917344D0 (en) 1999-07-24 1999-09-22 Zeneca Ltd Novel salt
AU7480800A (en) 1999-09-13 2001-04-17 3-Dimensional Pharmaceuticals, Inc. Azacycloalkanone serine protease inhibitors
WO2001019788A2 (fr) 1999-09-17 2001-03-22 Cor Therapeutics, Inc. BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
NZ517828A (en) 1999-09-17 2003-10-31 Millennium Pharm Inc Inhibitors having activity against mammalian factor Xa
WO2001038309A1 (fr) 1999-11-24 2001-05-31 Cor Therapeutics, Inc. INHIBITEURS DU FACTEUR Xa A BASE D'ACIDES β-AMINES, ASPARTIQUES ET DIAMINOPROPIONIQUES
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
CA2413241A1 (fr) 2000-06-29 2002-01-10 Bristol-Myers Squibb Pharma Company Inhibiteurs de la thrombine ou du facteur xa
CA2422873A1 (fr) 2000-09-29 2002-04-04 Wenhao Li Amides piperazine-2-un comme inhibiteurs du facteur xa
US20040067938A1 (en) 2000-09-29 2004-04-08 Penglie Zhang Quaternary amines and related inhibitors of factor xa
US20040082786A1 (en) 2000-09-29 2004-04-29 Bing-Yan Zhu Piperazine based inhibitors of factor xa
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
MXPA03003572A (es) 2000-11-22 2003-07-14 Yamanouchi Pharma Co Ltd Derivados de benceno sustituidos o sales de los mismos.
EP1343751A2 (fr) 2000-12-20 2003-09-17 Bristol-Myers Squibb Company Derives cycliques en tant que modulateurs de l'activite des recepteurs de chimiokines
WO2002079145A1 (fr) 2001-03-30 2002-10-10 Millennium Pharmaceuticals, Inc. Composes de benzamide, inhibiteurs ddu factor xa
EP1405852B9 (fr) 2001-06-20 2013-03-27 Daiichi Sankyo Company, Limited Derives de diamine
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
CN100545160C (zh) 2001-08-09 2009-09-30 第一制药株式会社 二胺衍生物
GEP20074098B (en) 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
RU2005123390A (ru) * 2002-12-24 2006-01-27 Дайити Фармасьютикал Ко., Лтд. (JP) Новые производные этилендиамина
KR20050110612A (ko) * 2002-12-25 2005-11-23 다이이찌 세이야꾸 가부시기가이샤 디아민 유도체

Also Published As

Publication number Publication date
US20100093785A1 (en) 2010-04-15
US20050020645A1 (en) 2005-01-27
WO2003000657A1 (fr) 2003-01-03
AR036102A1 (es) 2004-08-11
ZA200309866B (en) 2005-03-30
MY153231A (en) 2015-01-29
CY2015034I2 (el) 2016-04-13
US20050119486A1 (en) 2005-06-02
BE2015C046I2 (fr) 2021-07-19
US20110077266A1 (en) 2011-03-31
CY2015034I1 (el) 2016-04-13
FR15C0068I1 (fr) 2015-12-04
EP2343290A1 (fr) 2011-07-13
PT1405852E (pt) 2012-10-30
US7365205B2 (en) 2008-04-29
NL300760I2 (en) 2017-07-20
US20080015215A1 (en) 2008-01-17
US20090270446A1 (en) 2009-10-29
TWI298066B (en) 2008-06-21
HK1092461A1 (en) 2007-02-09
US20110312990A1 (en) 2011-12-22
US7342014B2 (en) 2008-03-11
CY1113054T1 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
FR15C0068I2 (fr) Derives de diamine
NO20035634D0 (no) Diamin-derivater
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
PT1406628E (pt) Derivados de tera-hidroquinolina
DE60216115D1 (de) BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
ATE312827T1 (de) 3-substituierte-4-pyrimidonderivate
DZ3439A1 (fr) Derives de 2-aminocarbonyl-9h-purine
DE50210707D1 (de) Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
DK1412328T3 (da) Dolastatin-10-derivater
DE60218501D1 (de) Einstellbarer fixateur
DK1419152T3 (da) HIV-hæmmende pyrimidin-derivater
DE60225563D1 (de) 4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
DE60214428D1 (de) 1, 4-dihydro-1, 4-diphenylpyridin-derivate
ATE425147T1 (de) Imidazolderivate
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
FR2810318B1 (fr) Derives de diamano-phenothiazine
DE60223031D1 (de) Arylpiperazin gebundene tetrahydroindolonderivate
MA27240A1 (fr) Derives d'imidazoquinoleine
ATE382601T1 (de) Substituierte 4-aminocyclohexanolderivate
FR2824557B1 (fr) Derives lipidiques de polythiouree
DE60202381D1 (de) Paroxetin-n-formyl-derivate
ATE382628T1 (de) Tetrahydrobenzfluorenderivate
NO20044405L (no) Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
ATA2892002A (de) Beschlag
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður